Hillstar Bio is a precision immunology company dedicated to developing innovative treatments for autoimmune diseases with significant unmet medical needs. Based in Boston's Seaport neighborhood, the company is advancing a promising portfolio of therapeutic programs, including its lead candidate targeting Cold Agglutinin Disease (CAD) and other conditions like Systemic Lupus Erythematosus (SLE). These diseases currently lack effective treatment options, and Hillstar aims to enhance patient outcomes through safer and more effective therapies. With a team of passionate drug developers, Hillstar prioritizes collaboration and fosters a culture of innovation, seeking to set new standards in the management of serious autoimmune disorders. The organization values diversity and is committed to creating an inclusive work environment for all.